Penn Capital Management Company LLC Has $679,000 Stake in ASP Isotopes Inc. $ASPI

Penn Capital Management Company LLC trimmed its position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 37.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 126,916 shares of the company’s stock after selling 75,228 shares during the quarter. Penn Capital Management Company LLC owned approximately 0.11% of ASP Isotopes worth $679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. UBS Group AG raised its stake in shares of ASP Isotopes by 150.3% in the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after acquiring an additional 1,445,165 shares in the last quarter. Marshall Wace LLP raised its stake in shares of ASP Isotopes by 3,669.1% in the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after acquiring an additional 1,245,184 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares in the last quarter. Rovida Investment Management Ltd raised its stake in shares of ASP Isotopes by 45.5% in the 3rd quarter. Rovida Investment Management Ltd now owns 3,200,000 shares of the company’s stock valued at $30,688,000 after acquiring an additional 1,000,000 shares in the last quarter. Finally, Jump Financial LLC bought a new position in shares of ASP Isotopes in the 3rd quarter valued at approximately $8,990,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ASPI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $6.67 on Thursday. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $5.12 and its two-hundred day moving average is $5.90. The company has a market cap of $839.75 million, a P/E ratio of -3.21 and a beta of 3.26. ASP Isotopes Inc. has a 12 month low of $3.92 and a 12 month high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.06. The company had revenue of $8.36 million for the quarter, compared to the consensus estimate of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

Insider Activity

In other news, COO Robert Ainscow sold 22,500 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $117,225.00. Following the sale, the chief operating officer directly owned 1,490,317 shares in the company, valued at approximately $7,764,551.57. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Duncan Moore sold 11,642 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $5.21, for a total value of $60,654.82. Following the sale, the director owned 1,044,928 shares in the company, valued at approximately $5,444,074.88. This represents a 1.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 90,704 shares of company stock worth $463,252. Company insiders own 14.40% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.